COMMUNIQUÉS West-GlobeNewswire

BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
29/07/2026
BURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026
29/07/2026
Conference Call Scheduled for August 5, 2026, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end [...]
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
29/07/2026
First BiTAC®-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology areas including [...]
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
29/07/2026
Conference Call to be Held Monday, August 3, 2026, at 8:30 am ET NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, [...]
Atavistik Bio Appoints Habib Dable to its Board of Directors
29/07/2026
Mr. Dable brings deep expertise in clinical development, commercialization, and corporate strategy to support Atavistik Bio’s next phase of growth CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Atavistik Bio, a [...]
Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence
29/07/2026
Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA ’s U.S. Market Share [...]
Shape Therapeutics Receives Research Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance SHP-201, a One-Time Gene Therapy to Treat Parkinson’s Disease
29/07/2026
Grant supports IND-enabling studies of an intravenously delivered, disease-modifying gene therapy designed to reduce alpha-synuclein in the brain regions most affected by Parkinson’s disease SEATTLE, July 29, 2026 ( [...]
Axogen, Inc. Reports Second Quarter 2026 Financial Results
29/07/2026
Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million ALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing [...]
Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET
29/07/2026
WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Option Care Health Announces Financial Results For The Second Quarter Ended June 30, 2026
29/07/2026
BANNOCKBURN, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Fortrea Reports Second Quarter 2026 Results
29/07/2026
Four consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: Revenues of $678.2 million Book-to-bill [...]
TRUE-See Systems Announces New Venture Funding
29/07/2026
TRUE-See’s AI-driven proprietary technology is designed to transform medical photography by making it accurate, reliable, versatile and easily accessible NEW ORLEANS, July 29, 2026 (GLOBE NEWSWIRE) -- TRUE-See Systems, [...]
Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026
29/07/2026
141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure [...]
Alira Health Establishes Annabel de Maria Memorial Scholarship to Inspire the Next Generation of Healthcare Leaders
29/07/2026
Annual scholarship continues the vision of Alira Health's late Chief Patient Officer by supporting future leaders committed to improving healthcare and patient outcomes BARCELONA, Spain, July 29, 2026 (GLOBE NEWSWIRE [...]
Hopstem Receives U.S. FDA IND Clearance and Fast Track designations for hNPC01 in Hemorrhagic Stroke and Traumatic Brain Injury-Expanding Clinical Development Across Three Major Brain Injury Indications
29/07/2026
HOUSTON, July 29, 2026 (GLOBE NEWSWIRE) -- Hopstem Biotechnology announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application and Fast Track designations for [...]
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
29/07/2026
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 29, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients [...]
Ceribell to Participate in the Canaccord Genuity 46th Annual Growth Conference
28/07/2026
SUNNYVALE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]
Solésence To Report Second Quarter 2026 Financial Results and Host a Conference Call on August 11
28/07/2026
ROMEOVILLE, Ill., July 28, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
28/07/2026
Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging | Highly sensitive multiplex [...]

Pages